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Abstract
The aim of the present study was to determine if the enzyme Aspergillus niger prolyl endoprotease (ANPEP), which degrades the immunogenic
proline-rich residues in gluten peptides, can be used in the development of new wheat products, suitable for gluten-sensitive (GS) individuals. We
have carried out a double-blind, randomised, cross-over trial with two groups of adults; subjects, self-reporting beneﬁts of adopting a gluten-free or
low-gluten diet (GS, n 16) and a control non-GS group (n 12). For the trial, volunteers consumed four wheat breads: normal bread, bread treated
with 0·8 or 1% ANPEP and low-protein bread made from biscuit ﬂour. Compared with controls, GS subjects had a favourable cardiovascular lipid
proﬁle – lower LDL (4·0 (SEM 0·3) v. 2·8 (SEM 0·2)mmol/l; P= 0·008) and LDL:HDL ratio (3·2 (SEM 0·4) v. 1·8 (SEM 0·2); P= 0·005) and modiﬁed
haematological proﬁle. The majority of the GS subjects followed a low-gluten lifestyle, which helps to reduce the gastrointestinal (GI) symptoms
severity. The low-gluten lifestyle does not have any effect on the quality of life, fatigue or mental state of this population. Consumption of normal
wheat bread increased GI symptoms in GS subjects compared with their habitual diet. ANPEP lowered the immunogenic gluten in the treated
bread by approximately 40%. However, when compared with the control bread for inducing GI symptoms, no treatment effects were apparent.
ANPEP can be applied in the production of bread with taste, texture and appearance comparable with standard bread.
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Coeliac disease is an autoimmune response to the major wheat
protein, gluten and affects approximately one in a hundred
individuals. However, general practitioners and gastro-
enterologists are encountering patients claiming gluten-related
symptoms without a deﬁnitive diagnosis of coeliac disease.
These individuals have been deﬁned as suffering from gluten
sensitivity(1). The diagnosis of non-coeliac gluten-sensitive
(NCGS) patients is difﬁcult, as is the management, because
there are no known biomarkers. It has been reported that
gluten-free diet (GFD) alleviates symptoms in subjects with the
condition(1). However, NCGS is not well characterised at pre-
sent and there is only a limited consensus on its presence and
diagnosis(2). It is also not clear what exactly are the dietary
requirements for this population and whether the affected
individuals can tolerate low doses of gluten as opposed to
following a strict GFD. As the majority of the gluten-sensitive
(GS) subjects are self-diagnosed, information is scarce on
whether their gluten intake is any different from that of the
general or coeliac population. Therefore, further characterisa-
tion of subjects claiming sensitivity to gluten is important to
better understand the aetiology of the syndrome and to ensure
that the dietary needs of people with the condition are
adequately met.
Gluten is a generic term for a family of proteins which include
polymeric (larger molecular weight) glutenins and monomeric
(lower molecular weight) gliadins. There is evidence that the
ingestion of gluten plays a part in the aetiology of coeliac disease,
inducing cell-mediated immunological responses in the small
intestine and ﬂattening of the mucosa(3). NCGS lacks the char-
acteristic serological and histological markers of coeliac dis-
ease(4,5), suggesting different patho-physiological mechanisms.
In addition, the diet component(s) involved in the pathogenesis
of NCGS have not as yet been identiﬁed. However, it is sus-
pected that gluten is a candidate, although there are some studies
showing that Fermentable, Oligo-, Di-, Mono-saccharides and
Polyols (FODMAP) might be the triggering factors(6). Other
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studies however report gluten being the culprit in NCGS indivi-
duals, in whom FODMAP intolerances have been ruled out(7).
More resent evidence also suggests that members of the non-
gluten α-amylase/trypsin inhibitor (ATI) family contained in
wheat(8) may play a role.
As the products for customers with gluten-related disorders
are often reported to be unsatisfactory in terms of palatability,
the manufacturers are seeking to develop new gluten-free
or gluten-detoxiﬁed alternatives. One approach, which has
received consideration, is the use of enzymes directed against
the immunogenic proline rich residues in gluten peptides(9).
Gluten is especially rich in proline, which renders the
immunogenic epitopes resistant to gastrointestinal (GI)
digestion(10,11). It has been reported that in vitro the enzyme
Aspergillus niger prolyl endoprotease (ANPEP), produced from
the fungus Aspergillus niger, is capable of degrading intact
gluten molecules and T cell stimulatory epitopes from gluten
into non-immunogenic, harmless fragments(12). ANPEP is also
highly efﬁcient in accelerating the degradation of both gliadin
and glutenin molecules in a GI model system and in the
stomach of healthy volunteers(13,14). However, one problem in
the use of enzymes such as ANPEP in baking is that they target
the digestion of gluten, which confers the unique visco-elastic
properties of the dough that allows it to be processed into bread.
Thus, we needed to determine if ANPEP could be used at levels,
which rendered the gluten harmless, but could be used in the
production of wheat products, comparable with standard gluten
content products in terms of taste, texture and appearance.
In this study we have investigated if ANPEP-treated bread is
suitable for consumption by subjects self-reporting beneﬁts
of adopting a low-gluten or GFD. In addition, we have char-
acterised this group of subjects by comparing them with a
non-GS control group.
Methods
Experimental bread
Four types of white bread were produced (Warburton Ltd.),
broadly following the Chorleywood bread process(15). The four
variants were as follows: a reference/control bread (the ﬂour used
was a bread-making grist of 11·9% protein at 14% moisture);
a protease-treated bread (treated with 0·8% ANPEP); a second
protease-treated bread (treated with 1% ANPEP); and a lower-
protein bread made from biscuit ﬂour (9·2% protein at 14%
moisture). These four treatments allowed us to investigate the
responses of self-deﬁned GS individuals to breads with decreas-
ing gluten content. The protease ANPEP was provided by DSM
Food Specialities B.V. at an activity of 43 propyl peptidase units/g
(WO2005/027953). Other additions, such as salt, yeast and minor
processing additives were constant throughout and in accordance
with standard commercial practice however, certain minor
adjustments were made to the addition of water in the dough to
allow the breads to be processed correctly.
The experimental bread was delivered sliced (35 g/slice),
with the crusts removed from each loaf. It was packed in
transparent bags, labelled as bread A, B, C or D. The code was
held by an independent observer. In a preliminary test, ten
healthy individuals were unable to detect any differences in the
taste, smell and appearance of the four breads. The bread was
kept frozen until required.
The proteins of the bread were measured by the Dumas
combustion method, using Leco FP528 protein analyser (LECO)
according to accepted standards and by Gluten-Tec® ELISA
(EuroProxima) for quantitative detection of α-20 gliadin and
gliadin fragments in food and competitive RIDASCREEN®
Gliadin ELISA (R-Biopharm AG) for analysis of R5 epitope. In
the case of the R5 ELISA (lower limit of quantiﬁcation 10mg
gluten/kg and reproducibility around 37%), gliadin was
extracted by the universal prolamin and glutelin extractant
solution procedure of Mena et al.(16), whereas in the case of the
α-20 ELISA (lower limit of quantiﬁcation 153 µg peptide/kg and
reproducibility for incurred baked matrices of around 45%),
gluten extraction used 60%-ethanol-dithiothreitol according
to the manufacturers’ instructions.
Subjects
This study was conducted according to the guidelines laid down
in the Declaration of Helsinki and all procedures involving
human subjects were approved by the Rowett Institute Ethics
Committee in April 2014. Recruitment was through a variety of
sources including press releases, radio adverts, newspaper
adverts, posters, ﬂyers and presentations to the public. Written
informed consent was obtained from all subjects. The study took
place between June 2014 and June 2015. Adults from two groups
were invited to participate – those who believed they experience
sensitivity to gluten, but were willing to consume breads made of
wheat ﬂour (including normal gluten containing bread) and
healthy volunteers, who acted as a control group.
A total of 153 subjects expressed interest in the study how-
ever, many of these declined to participate in the trial as they
were following a strict GFD and were not prepared to undergo
gluten rechallenge. The recruitment process is illustrated in
Fig. 1. Those subjects, who were willing to continue with the
trial (n 62), were invited to complete a health and lifestyle
questionnaire (screening visit) to assess their general health and
their sensitivity to gluten/wheat. For the evaluation of dietary
compliance with the GFD, a veriﬁed ﬂow chart(17,18) was used.
This numerical ﬁve-level score system is based on strategies that
subjects use to avoid eating gluten(17). Initial investigation for
coeliac disease was through a questionnaire incorporating the
following questions: ‘Have you ever been tested for coeliac
disease? If yes, how long ago was the test done?’; ‘Did you have
a blood test for coeliac disease? Was the blood test: positive;
negative; I do not know’; ‘Did you have a duodenal biopsy?
Was the biopsy: positive; negative; I do not know’. All volun-
teers who reported a diagnosis of coeliac disease (CD) were
excluded. Those volunteers who completed tests for CD
(duodenal biopsy or immunological tests) but the CD diagnosis
was not conﬁrmed were invited to participate in the study.
These volunteers believed that avoiding gluten helped to
reduce their discomfort. Volunteers were also excluded if they
had been previously diagnosed with dermatitis herpetiformis,
wheat allergy or GI disorders; were unable to give written
informed consent; were on medications for treatment of GI
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symptoms or were taking digestive enzymes; were pregnant/
breast-feeding; had poorly controlled psychiatric disease or had
any other signiﬁcant health issue. A total of thirty-two subjects
were enrolled in the study and were randomly allocated by an
independent statistician in a double-blind, cross-over fashion to
the treatments (breads). The volunteers were invited to com-
plete the Quality of Life (36-Item Short Form Health Survey
(SF-36))(19), Physical Activity (Beacke)(20) and Depression,
Anxiety and Stress (DASS 21)(21) questionnaires, whereas on
their habitual diet and before the interventions began. In all,
twenty-eight subjects (twenty female and eight male) com-
pleted the trial (sixteen self-reported sensitive to gluten subjects
and twelve healthy volunteers). The reasons for drop-outs were
as follows: reappearance of severe GI symptoms (scoring above
80 on a 100mm visual analogue scale (VAS)) while on trial
breads (two GS volunteers); non-compliance with study diaries
(one GS volunteer); and noncompliance with bread consump-
tion (one GS volunteer).
Study design
Blood samples from both, control and GS groups, were col-
lected between 07.00 and 10.00 hours after 10 plus hours of
fasting before the interventions began, using serum-, EDTA- or
heparinised- evacuated tubes (BD Vacutainer® tubes; Becton
Dickinson UK Ltd). Serum and plasma were stored at −70°C
until they were analysed.
After 1 week on their habitual diet (week 0), subjects were
randomly allocated in a double-blind, cross-over fashion to one
of the four breads (Fig. 2). The trial participants were instructed
to consume each treatment bread for 1 week (3 slices/d –
105 g), replacing the bread they normally ate with the experi-
mental bread. For the duration of the study, the volunteers were
asked to continue to eat their habitual diet, but to refrain from
eating gluten containing foods (as well as other foods), which
they considered to cause GI discomfort. The experimental
period was followed by a 14-d wash-out period before crossing
over to the next bread. Subjects experiencing reappearance of
intolerable symptoms on a treatment bread were asked to cease
the study bread of that particular intervention but to continue to
ﬁll in the GI symptoms and daily fatigue diaries. Subjects were
allowed to continue with the trial if they wished. Compliance
was assessed verbally at regular reviews and counting the slices
of bread left at the end of the treatment week.
Gastrointestinal symptoms and fatigue
GI symptoms were assessed using 100mm VAS(4). Perception of
fatigue was evaluated by the Daily Fatigue Impact Scale
(D-FIS)(22) − an eight-item self-report questionnaire, with ﬁve
options of response per item (from 0=no problem, to 4= extreme
problem). The D-FIS score is derived from the sum of the ordinal
scores obtained for each item with possible score range of 0–32.
For comparison, VAS ranging from 0 to 100mm and with higher
values indicating more tiredness was also used(4). Visual analogue
scales for GI symptoms and fatigue and D-FIS questionnaire were
completed daily during baseline (week 0) while on their habitual
diet; during treatment weeks (weeks 1, 4, 7, 10) and during the
second wash out week between each treatment (weeks 3, 6, 9)
when the volunteers were following their habitual diet (see Fig. 2).
Enquiries
n 153
Willing to continue
with the trial
n 62
Health, lifestyle and 
dietary 
compliance 
questionnaires
Enrolled in the study
n 32
SF-36, Beacke and
DASS 21 
questionnaires
GS
n 20
Control
n 12
Drop out
n 4
Completed
the trial
GS
n 16
Completed
the trial
Control
n 12
Fig. 1. Study recruitment. SF-36, 36-Item Short Form Health Survey, DASS 21,
Depression, Anxiety and Stress Scale; GS, gluten sensitive.
Week
0
Baseline week
Screening
Weeks
1 4 7 10
Treatment week
Weeks
2+3 5+6 8+9
Washout  week
Health screening
If subject suitable:
Quality of Life
(SF-36)
Physical Activity 
(Beacke)
Depression, Anxiety 
and Stress (DASS 21)
Fasting blood sample
Blood pressure
Anthropometrics
GI symptoms diary
Daily fatigue diary
Random allocation to 
bread A, B, C or D
in a double-blind, 
cross-over fashion  
GI symptoms diary
Daily fatigue diary
Weeks  3  6  9 only
GI symptoms diary
Daily fatigue diary
Fig. 2. Study design. After 1 week of a baseline period consuming their habitual diet (week 0), subjects were randomly allocated in a double-blind, cross-over fashion
to the four breads, labelled as bread A, B, C or D. Each experimental period was followed by a 14-d wash-out period before crossing over to the next bread. SF-36,
36-Item Short Form Health Survey, DASS 21, Depression, Anxiety and Stress Scale; GI, gastrointestinal.
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Serum analysis
IgA levels in serum were measured using the Konelab analyser.
IgA was purchased from Thermo Fisher Scientiﬁc. The detection
limit was 0·2 g/l. The concentrations of anti-human-tissue-
transglutaminase IgA (anti-htTG IgA) (Immundiagnostik AG),
gliadin IgA and IgG (Genesis Diagnostics Ltd) and zonulin
(Immundiagnostik AG) in the serum were measured using
speciﬁc ELISA. Samples classed as negative were as follows:
<22AU/ml (htTG IgA); <4U/ml (gliadin IgA); <10U/ml
(gliadin IgG); normal reference range for zonulin was 34 ng/ml
(±14 ng/ml) (data supplied by the manufacturer of the kit).
Whole blood analysis
The full blood count was determined with a SYSMEX
(Eightcheck-3WP Assay Sysmex Europe GmbH) on EDTA
treated blood. Measurements were performed within 30min of
collection, according to the manufacturer’s instructions.
Lipid and blood glucose analyses were determined using an
Alere Cholestech LDX (LDX Lipid Proﬁle +Glucose cassette
supplied by Alere Ltd) on heparin treated blood. Measurements
were performed within 30min of collection, according to the
manufacturer’s instructions.
The determination of basophil activation upon wheat aller-
gen stimulation (Flow2 CAST test) was carried out using whole
EDTA anti-coagulated blood. Flow2 CAST and wheat allergen
were purchased from BÜHLMANN Laboratories AG. Analysis
were performed according to the manufacturer’s instructions
on the day of blood collection, using a Becton-Dickinson
FACSCalibur ﬂow cytometer.
Statistical analysis
Power calculations. The study aimed to detect a minimum shift
of 10 VAS units (out of a total of 100 units) in GI scores due to
the consumption of the treatment breads, within each of the
control and GS groups. Assuming a within volunteer spread of
10 VAS units, a power of 90% and 5% signiﬁcance, this
required twelve volunteers (per group). To allow for dropout
and non-compliance this was raised to sixteen volunteers for
each group.
Assessment of differences in baseline characteristics
between control and gluten-sensitive groups. Baseline
measurements of the control and GS groups were compared by
independent-samples t test. In addition, differences in baseline
blood measurements between the two groups were also com-
pared by analysis of variance with covariate adjustment for age
and BMI.
Assessment of suitability of Aspergillus niger prolyl
endoprotease treated bread for consumption by gluten-
sensitive volunteers, based on gastrointestinal and daily
fatigue scores. First, the scores from the habitual diet (obtained
during week 0 and the 2nd week of each washout period,
weeks 3, 6 and 9) were analysed to investigate trends over time,
based on analysis of variance with volunteer as random effect
and week, group and their interaction as ﬁxed effects, followed
by post hoc t test comparisons. This indicated that for several GI
symptoms the scores were signiﬁcantly (P< 0·05) higher at
week 0 and declined over time. This is a well-known psycho-
logical effect when participants are entering into a trial(23).
Second, the GI and daily fatigue scores obtained during the
treatment weeks (weeks 1, 4, 7 and 10) were analysed by
ANOVA with volunteer as random effect and with treatment,
group and their interaction as ﬁxed effects, and with the cor-
responding habitual diet score from the preceding washout
week as covariate. Third, as comparison of the treatment diets
against the habitual diet was of speciﬁc interest, an alternative
analysis was also performed, where the scores of the habitual
diet (weeks 0, 3, 6 and 9) were averaged and, together with the
four treatments, analysed as ANOVA with volunteer as random
effect and with treatment (including the habitual diet), group
and their interaction as ﬁxed effects. The overall ﬁndings of this
third analysis were similar to those from the covariate analysis
(second analysis), and therefore ﬁndings from the latter are
presented. This was followed by post hoc t tests to compare the
scores obtained from the four treatment breads against those of
the habitual diet for both control and GS groups.
For all statistical analyses, visual inspection of the residual
plots indicated that assumptions of normality and constant
variance had been met and therefore no transformations were
needed. A P value<0·05 indicated statistical signiﬁcance. Data
are presented as means with their standard errors. All statistical
analyses were conducted in Genstat 17th Edition (Release 17.1;
VSN International Ltd).
Results
Subjects
The baseline characteristics of the subjects in both treatment
groups are shown in Table 1. Data are only reported for those
subjects who completed the study. There were no signiﬁcant
differences in the baseline characteristics between the two
groups with respect to age, BMI, systolic and diastolic blood
pressure and pulse.
Analytical results of the breads
Typically 80% of the protein in bread is gluten(24). In our study,
the control bread contained 7·88% protein, whereas the bread
Table 1. Baseline characteristics of the control (CON) and gluten-sensitive
(GS) treatment groups
(Mean values with their standard errors)
CON group GS group
Mean SEM Mean SEM P*
No. of subjects 12 16
Age (years) 58·8 2·9 51·1 3·6 0·12
BMI (kg/m2) 26·0 1·3 23·6 0·7 0·081
Systolic blood pressure (mmHg) 135·5 7·2 124·2 4·7 0·18
Diastolic blood pressure (mmHg) 74·5 3·1 72·8 2·7 0·69
Pulse (heartbeats/min) 64·2 1·8 61·9 2·1 0·43
* Two-sample t test.
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prepared with biscuit ﬂour was approximately 16% lower in
protein than the control bread. As a consequence of the addi-
tion of the enzyme, both ANPEP treated breads contained more
protein in relation to the control bread (Table 2).
The level of gluten degradation was evaluated by two dif-
ferent ELISA assays, one sensitive to the α-20 gliadin, the other
to the R5 epitope. Both assays showed that ANPEP treated
breads contained approximately 40% less immunoreactive
gluten than the control bread. However, increasing the con-
centrations of ANPEP from 0·8% w/w to 1·0% w/w did not
increase the degradation of the gluten. The gluten content of
bread prepared with biscuit ﬂour was approximately 16% lower
than that of the control bread and consistent with its lower
protein content (Table 3).
Lifestyles in relation to gluten consumption
During the process of recruitment the subjects’ experiences,
personal histories and understanding of gluten were assessed
using questionnaires and an interview (sixty-two subjects were
interviewed, twelve of these were healthy controls). Of the ﬁfty
GS volunteers with no diagnosis of coeliac disease, that com-
pleted the questionnaires, eleven (22%) followed a strict GFD
with the remaining thirty-nine subjects (78%) following a low-
gluten lifestyle by mainly substituting wheat bread and pasta
with GF options or removing those items from their
diet altogether. With the exception of two subjects, those who
were following a strict GFD declined to participate. Those
individuals, who consented to take part, were mostly GS
subjects with a low-gluten lifestyle, whose habitual diet still
contained variable quantities of gluten. Fig. 3 shows the range
and frequency of GI and extra-intestinal manifestations (self-
perceived as gluten-related), reported by the GS study group
before adopting a low-gluten lifestyle.
Biomarkers for coeliac disease and wheat allergy
The total IgA levels were within the normal range in all partici-
pants, between 0·7 to 3·6 g/l. For all the GS participants the IgA
anti-tTG values for CD-associated antibodies were lower than the
accepted levels for diagnosis of CD (<22AU/ml). Gliadin IgA
was weakly positive (value 5U/ml IgA) for one participant in the
GS group (cut-off values indicated by the manufacturer>4U/ml
IgA), the levels for all other samples in the GS and control groups
were negative. A positive result for Gliadin IgG was observed in
18% of the GS participants who had values >10U/ml IgG. There
was also one positive sample in the control group. Serum zonulin
levels were in the (34 (SEM 14)ng/ml) range (as per manu-
facturer’s data sheet) for all participants in both groups, with the
exception of one control sample. No GS subjects with a wheat
allergy were identiﬁed upon basophil activation with a wheat
allergen (data not shown).
Whole blood results
The GS subjects had 9% lower erythrocyte concentration
(P= 0·02), 6% higher mean corpuscular volume (MCV)
(P= 0·002), 4% higher mean corpuscular Hb (P= 0·03), 13%
higher platelet distribution width (PDW) (P= 0·01) and 10·5%
higher mean platelet volume (MPV) (P= 0·005) in comparison
with the control group (independent-samples t tests). The
values remained signiﬁcantly different after adjusting for age
and BMI as covariates (Table 4).
The GS group had 18% lower total cholesterol levels than
the control group (independent-samples t test; P=0·018).
Table 2. Analysis of the experimental breads
(Mean values with their standard errors; n 2)
Protein
(%)
Moisture
(%)
Types of bread Mean SEM Mean SEM Protein dmb (%)
Control bread 7·88 0·01 43·1 0·2 13·8
Biscuit flour bread 6·63 0·01 38·1 0·2 10·7
0·8% ANPEP (340 PPU/kg) 8·64 0·01 39·2 0·1 14·2
1% ANPEP (430 PPU/kg) 8·65 0·01 39·1 0·1 14·2
dmb, DM base; ANPEP, Aspergillus niger prolyl endoprotease; PPU, propyl
peptidase units.
Table 3. Gluten content of the bread*
(Mean values with their standard errors; n 3)
α-20 gliadin R5 epitope
Gluten – Rel. (%) Gluten – Rel. (%)
Types of bread Mean SEM Mean SEM
Control bread 100·0a 2·5 100·0a 4·4
Biscuit flour bread 88·1a 4·9 83·6b 1·2
0·8% ANPEP 58·4b 2·7 57·1c 3·6
1% ANPEP 61·5b 1·1 59·0c 2·9
ANPEP, Aspergillus niger prolyl endoprotease.
a,b,c Mean values in the same column with unlike superscript letters are significantly
different – post hoc comparisons (P<0·001).
* Data are normalised to the control bread (100%). Data were analysed by one-
way ANOVA.
0 10 20 30 40 50 60
Skin problems/itchiness
Insomnia
Numbness in legs/arms
Cravings for carbohydrates
‘Foggy mind’
Thyroid problems
Muscle or joint pain/stiffness
Headaches
Fatigue
Difficulty relaxing
Intestinal gas
Constipation/diarrhoea
Abdominal cramping
Bloating or swollen tummy
% of gluten-sensitive subjects
Fig. 3. Frequency of gastrointestinal and extra-intestinal symptoms reported by
the subjects in the gluten-sensitive group before adopting a low-gluten lifestyle.
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However, this was not signiﬁcant after adjustment for age and
BMI (P=0·082). Subjects in the GS group had signiﬁcantly higher
HDL values in comparison with the control group (independent-
samples t test; 1·4 (SEM 0·1) v. 1·7 (SEM 0·1); P=0·021). After
adjustment for age and BMI, differences in HDL were no longer
signiﬁcant. GS subjects had 30% lower LDL levels (P= 0·005) and
the LDL:HDL ratio was 3·2 (SEM 0·4) in the control v. 1·8 (SEM 0·2)
in the GS group (P= 0·003). These remained signiﬁcant after
adjustment for age and BMI (for LDL P= 0·008; for LDL:HDL ratio
P= 0·005) (Table 4). There were no differences in the blood
glucose concentrations between the two groups (Table 4).
Gastrointestinal symptoms
There were no differences in the severity of the GI symptoms
measured (P> 0·095) between the control and GS group
while on their habitual diet (Table 5). There were no signiﬁcant
effects of dietary treatment, and there were no signiﬁcant
interactions with participant group. There were however
differences between the two groups after consumption of
the experimental breads. The scores for bloating (15 VAS
units; P= 0·008), ﬂatulence (13 VAS units; P= 0·003), pain
(8 VAS units; P= 0·045) and rumbles (8 VAS units; P= 0·04)
Table 4. Comparison of full blood count (FBC), lipid profile and blood glucose measurements between control (CON) and gluten-
sensitive (GS) group at baseline
(Mean values with their standard errors)
CON group GS group
FBC, lipid and blood glucose parameters Unit Mean SEM Mean SEM P *
Leucocyte concentration ×103/µl 5·0 0·4 5·0 0·3 NS
Erythrocyte concentration ×106/µl 4·6 0·1 4·2 0·1 0·022
Hb concentration mmol/l 2·09 0·02 2·03 0·05 NS
Haematocrit % 40·1 0·4 39·1 0·8 NS
Mean corpuscular volume fl 88·1 1·0 92·4 0·8 0·002
Mean corpuscular Hb pg 29·8 0·3 31·1 0·4 0·022
Mean cell (erythrocyte) Hb concentration mmol/l 5·24 0·02 5·21 0·03 NS
Platelet concentration × 103/µl 230·6 13·7 212·3 11·6 NS
Percentage of lymphocytes % 33·2 3·0 34·3 1·9 NS
Percentage of basophils, eosinophils and monocytes % 9·7 0·9 8·7 0·5 NS
Percentage of neutrophils % 57·2 3·2 57·0 2·1 NS
Lymphocyte concentration ×103/µl 1·6 0·1 1·6 0·1 NS
Basophil, eosinophil and monocyte concentration ×103/µl 0·5 0·0 0·4 0·0 NS
Neutrophil concentration ×103/µl 3·0 0·4 2·9 0·3 NS
Erythrocyte distribution width-SD fl 44·3 0·8 46·5 0·6 0·012
Erythrocyte distribution width-CV % 12·4 0·2 12·4 0·2 NS
Platelet distribution width fl 10·7 0·2 12·1 0·4 0·027
Mean platelet volume fl 8·5 0·1 9·4 0·2 0·020
Plateletcrit % 0·2 0·0 0·2 0·0 NS
Total cholesterol mmol/l 5·8 0·3 4·8 0·2 0·082
TAG mmol/l 1·2 0·2 0·9 0·1 NS
HDL mmol/l 1·4 0·1 1·7 0·1 NS
LDL mmol/l 4·0 0·3 2·8 0·2 0·008
Glucose mmol/l 4·9 0·2 4·9 0·1 NS
LDL:HDL 3·2 0·4 1·8 0·2 0·005
* From ANOVA with age and BMI as covariates. Control group (n 12), GS group (n 16).
Table 5. Gastrointestinal (GI) symptoms experience in control (CON) and gluten-sensitive (GS) groups before and after consumption of different treatment breads†
(Mean values with their standard errors)
Habitual diet Control bread Biscuit flour bread 0·8% ANPEP bread 1% ANPEP bread
CON GS CON GS CON GS CON GS CON GS
GI symptoms Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Nausea 5·1 2·7 6·0 1·9 2·7 0·9 6·7 1·9 4·2 1·3 8·1 2·2 5·6 3·1 8·9 2·5 5·4 2·4 8·4 2·1
Bloating 6·9 2·8 15·5 4·0 5·0 1·5 19·0 3·5 5·8 2·1 19·1 4·3 5·8 2·9 20·9 5·1 6·1 2·2 20·0 3·4
Flatulence 11·0 2·9 19·6 3·4 9·2 2·2 24·3 3·4 11·1 2·8 28·6** 3·8 12·4 4·1 22·3 4·7 11·0 2·5 24·6 3·3
Pain 6·9 2·9 9·6 2·5 4·5 1·7 16·3** 3·2 5·0 2·0 12·0 2·7 6·1 2·9 11·5 3·6 5·6 2·1 12·4 2·5
Rumbles 7·9 3·1 12·4 2·8 6·2 2·5 17·5** 3·2 7·2 2·3 17·2* 3·3 8·9 3·2 13·3 3·2 7·6 3·1 16·2 2·5
ANPEP, Aspergillus niger prolyl endoprotease.
Significance of comparison against the habitual diet within group: * P<0·05, ** P<0·01.
† Control group (n 12), GS group (n 16). Data were analysed by ANOVA with random effect for volunteer and fixed effects for diet, group and its interaction. The effect of group was
significant for bloating, flatulence, pain and rumbles. There were no significant effects of diet or its interaction with group. Comparison symptom scores of the various test breads
against those observed during the habitual diet was of specific interest and therefore post hoc t test was performed to compare, within each group, GI symptoms during the
treatment breads against symptoms when following the habitual diet.
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were higher in the GS group when compared with the
control (Fig. 4).
Of speciﬁc interest was the comparison of GI symptoms
while on the experimental breads against the symptoms
observed when following the habitual diet. So although there
was no overall signiﬁcant effect of treatment, post hoc testing
was performed to compare, within each group, the experi-
mental bread against the habitual diet. When comparing the
breads against habitual diet within the control group, none of
the experimental breads had any signiﬁcant effects on the GI
symptoms measured. For the GS group however, consumption
of all experimental breads numerically increased GI symptoms
severity in comparison with the normal habitual diet (Table 5).
These increases reached statistical signiﬁcance for some GI
symptoms only with control bread (pain, 10 VAS units;
P= 0·007; rumbles, 11 VAS units; P= 0·040) and bread made
with biscuit ﬂour (ﬂatulence, 21 VAS units; P= 0·006), with
rumbles showing a tendency to increase (rumbles, 9 VAS units;
P= 0·052) (Table 5).
Extra-intestinal symptoms
The comparison of the fatigue scores (using D-FIS) in the group
of healthy individuals v. the GS group, showed numerically
better scores in the healthy controls (e.g. lower level of fatigue)
compared with the GS group, but this did not reach statistical
signiﬁcance (P> 0·05) (Table 6). The same pattern was
observed with the scoring on the fatigue VAS scale.
The Baecke questionnaire was used for the evaluation of
habitual physical activity. It consists of sixteen questions and
separates the person’s physical activity into three categories:
physical activity during work, sports and leisure time.
The GS group had a statistically signiﬁcant higher leisure index
compared with the control group (2·6 v. 3·3; P= 0·006)
(Table 7).
SF-36 survey for measurement of health status yields an
eight-subscale proﬁle of functional health and well-being.
Comparison of the SF-36 scores did not reveal any
statistically signiﬁcant differences between the control and GS
group with respect to any of the SF-36 subscales
(Table 7).
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Fig. 4. Gastrointestinal symptoms experience in the control and gluten-
sensitive groups. Values are means, with their standard errors over all five
treatments combined (habitual diet and four treatment breads). Control group
(n 12, ), gluten-sensitive (GS, ) group (n 16). Data were analysed by
ANOVA with random effect for participants and fixed effects for group, treatment
and their interaction. Significant effects for group: * P< 0·05, ** P< 0·01. There
were no significant effects for treatment and its interaction with group. VAS,
visual analogue scale.
Table 6. Comparison of fatigue experience between control (CON) and gluten-sensitive (GS) groups before and after consumption of different treatment breads
(Mean values with their standard errors)
Type of bread*
Habitual diet Control Biscuit flour 0·8% ANPEP 1% ANPEP P†
GI symptoms Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM grp treat grp × treat
Control group (D-FIS) 2·9 1·4 2·4 1·3 1·6 0·8 2·3 1·1 2·1 0·9
Gluten-sensitive group (D-FIS) 5·1 1·8 6·4 1·8 4·4 1·3 6·1 2·0 5·2 1·6
0·14 0·16 0·71
Control group (VAS) 13·5 5·7 11·1 5·2 10·0 4·5 14·4 5·9 12·3 4·8
Gluten-sensitive group (VAS) 19·3 4·8 24·5 5·2 19·2 3·8 23·8 5·3 16·4 3·7
0·21 0·20 0·37
ANPEP, Aspergillus niger prolyl endoprotease; grp, group; treat, treatment; D-FIS, Daily Fatigue Impact Scale; VAS, visual analogue scale.
* n 12 for control group; n 16 for GS group.
† Data were analysed by ANOVA with random effect for participants and fixed effects for grp, treat and their interaction.
Table 7. Comparison of the indices of physical activity, 36-Item Short
Form Health Survey (SF-36) scale and Depression, Anxiety and Stress
Scale (DASS-21) subscales between control (CON, n 12) and gluten-
sensitive (GS, n 16) group at baseline
(Mean values with their standard errors)
CON group GS group
Physical activity (Baecke) Mean SEM Mean SEM P*
Work index 2·4 0·2 2·5 0·1 0·77
Sport index 2·2 0·2 2·7 0·2 0·075
Leisure index 2·6 0·2 3·3 0·1 0·006
SF-36 subscales
Physical functioning 86·7 3·7 93·8 1·7 0·1
Role – physical 91·7 8·3 78·1 10·2 0·34
Bodily pain 87·7 4·4 75·8 5·4 0·12
General health 80·1 3·9 81·1 4·2 0·87
Vitality 67·5 5·0 63·1 5·6 0·58
Social functioning 94·8 2·9 89·1 4·8 0·36
Role – emotional 91·7 8·3 91·7 5·7 1
Mental health 80·7 3·3 75·8 3·9 0·36
DASS-21 subscales
Stress 9·2 2·5 9·1 1·9 0·97
Anxiety 4·2 1·3 4·2 1·0 0·98
Depression 3·4 1·2 5·1 1·9 0·5
* One-way ANOVA adjusted for age and BMI.
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The Depression, Anxiety and Stress Scale is a twenty-one-
item self-report scale designed to measure the emotional states
of depression, anxiety and stress. There were no statistically
signiﬁcant differences between the control and GS groups with
respect to the three DASS-21 subscales (Table 7).
Discussion
This study shows that individuals who are self-deﬁned as being
sensitive to gluten differ from healthy controls in several
measurable ways and show an increase in the severity of GI
symptoms when challenged with normal bread.
Two distinct groups of GS subjects were identiﬁed: those
who follow a strict GFD (22% of those who responded) and
those who follow a low-gluten lifestyle by removing ‘normal’
bread and pasta (and occasionally other gluten containing
items) from their diets or substituting them with GF options as a
relatively easy way of avoiding excess gluten. The attitude to a
strict GFD depends on personal experience; individuals with
severe symptoms are committed to a GFD because of the
impact it has on their health, whereas those with mild dis-
comfort focus on following a low-gluten lifestyle. The qualita-
tive data from both, the questionnaire and from interviews with
the volunteers, suggest that whilst this latter group self-deﬁne
themselves as being sensitive to gluten, they still have a variable
but reduced gluten intake and are not gluten-free.
Bread-making wheat typically contains ca 11% protein, 80% of
which is gluten. This equates to an intake of approximately 9g
of gluten/100g of bread(24). Consumption of bread in the UK is
estimated to be approximately 90g/d(25,26), thus average adult
consumption of gluten in bread is approximately 8g/d. Three
slices of the control bread provided the volunteers with 6·6g of
gluten/d. The biscuit ﬂour bread provided the volunteers with
around 5·6g gluten/d. Treatment of the ﬂour with ANPEP reduced
the amount of gluten by approximately 40% and provided the
volunteers with 2·6g of gluten/d. It is unclear why there was no
additional reduction of the gluten content in bread treated with 1%
ANPEP (as was anticipated) when compared with 0·8% ANPEP.
There were no differences in the severity of the GI symptoms
measured between the control and GS groups while on their
habitual diet, suggesting that following a low-gluten lifestyle
reduces the symptoms to tolerable levels in those GS sufferers
with mild complaints.
The absence of GI symptoms in the control group suggest
that the proline-speciﬁc ANPEP is well tolerated and can be
used in the production of bread which retains taste, texture and
appearance despite the 40% reduction of immunoreactive
gluten. In contrast, the individuals in the GS group experienced
more noticeable GI symptoms while consuming the experi-
mental breads. When the data were combined (Fig. 4), the
measured GI symptoms in the control group were within the
physiological range (<10mm VAS), effectively no symptoms,
whereas the GS group reported mild GI discomfort (up to
30mm VAS). Indeed, the majority of GS subjects, who agreed to
participate in the trial, reported during the screening process
that they experienced mild symptoms. Furthermore, two of the
participants who reported more severe symptoms (and were on
a strict GFD) dropped out during the 1st treatment week when
consuming either control bread or bread made with biscuit
ﬂour. Therefore, it is possible that an unintended sample bias
has been introduced as the true effect is underestimated by
excluding volunteers in the higher scoring range. This may be
an important weakness in this and similar studies and should be
considered in future designs.
All of the experimental breads numerically increased the
severity of the GI symptoms experienced by the GS group in
comparison with their habitual diet (Table 5). These increases
reached signiﬁcance for some GI symptoms only with the
control and biscuit ﬂour bread. Although the ANPEP bread
failed to reach statistical difference for increasing symptoms in
comparison with the subjects’ habitual diet, the overall magni-
tude of the effects were similar for all four treatments. This may
be due to levels of gluten in the ANPEP bread being insufﬁ-
ciently reduced. Also, the absence of a treatment effect needs to
be considered in the light of the difﬁculties encountered
working with this group of subjects. A nocebo effect, a strong
anticipatory symptomatic response, is often reported in NCGS
populations(8,27) and there is a possibility that the positive
symptomatic responses observed across all treatment arms are a
result of a nocebo effect. A placebo, gluten-free treatment, was
not included in this trial as it is virtually impossible to produce
gluten-free bread, with similar qualities of taste and texture to
bread prepared with wheat ﬂour. As volunteers would have
been readily able to distinguish the gluten-free product, a
placebo would have been rendered useless.
The investigation into the exclusion of coeliac disease and
wheat allergy was initially through health screening and gluten
sensitivity questionnaires and an interview. There was con-
siderable variation in the pathway and time of the diagnostic
tests for the previous exclusion of coeliac disease and wheat
allergy. Most of the participants had not had a duodenal biopsy
as their GP ruled out the diagnosis based on negative serology
tests. These tests took place between 5 months and 18 years
before the start of the study.
The National Institute for Health and Care Excellence
guideline published in September 2015 states that any test for
CD is accurate only if a gluten-containing diet is eaten during
the diagnostic process and that some gluten has to be eaten in
more than one meal every day for at least 6 weeks before
testing(28). IgA tissue transglutaminase (IgA tTG) is most com-
monly used as the ﬁrst test to detect the presence of coeliac
disease antibodies. This test should be done after testing for IgA
deﬁciency. IgA deﬁciency is deﬁned as total IgA <0·07 g/l and
will result in a false negative result when tested for IgA anti-
body(28). As the participants in this study were following a low-
gluten diet as opposed to a GFD and considering the variations
in their previous experience in testing for CD we performed in-
house CD diagnosis tests as described above. However,
although all GS participants had negative IgA tTG serology,
there is still the possibility that the levels of gluten intake in their
diet were not sufﬁcient to trigger a high enough titre for
detection of tTG antibodies.
Besides the use of the ‘anti-self’ tTG antibodies, we also
performed measurements for ‘anti-gluten’ antibodies – anti-
gliadin IgG and IgA. These have been previously reported
to have high titres in subjects with gluten sensitivity(29) and
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anti-gliadin IgG test was positive in 57% of the cases in subjects
consuming normal gluten-containing diet(29). In our study
the anti-gliadin IgG test was positive in only 18% of the GS
participants and there was one positive sample in the control
group. One possible explanation for the differences in our
results is that the low-gluten diet did not sufﬁciently challenge
the production of anti-gliadin IgG in some of the participants.
Indeed, it is a widely held view that IgG testing can be used to
monitor exposure to gluten, but a positive test does not conﬁrm
the presence of food intolerance(30).
Zonulin is a type of protein involved in the regulation of
intercellular tight junctions of the intestinal cells(31). Gluten is
one of the most powerful triggers for the production and release
of zonulin(32) and a link between zonulin and diseases such as
coeliac disease and dermatitis herpetiformis has already been
established(32,33). For this reasons we investigated zonulin levels
in self-deﬁned GS subjects on a low-gluten diet and compared
the results to the healthy controls. In this study we ﬁnd no
elevated levels of serum zonulin the GS participants.
Our results show a trend for lower total cholesterol level and
signiﬁcantly lower LDL levels (P= 0·008) and LDL:HDL ratio in
the GS group, when compared with the non-GS group
(Table 4). Coeliac disease is associated with low cholesterol
levels, which is thought to contribute to a favourable cardio-
vascular risk proﬁle(34,35). Our ﬁndings conﬁrm similarities in
the lipid proﬁle of gluten-related disorders, suggesting that the
possible mechanisms involved in altering this proﬁle may be
linked to the ingestion of gluten.
Anaemia can be the only ﬁnding in some patients with coe-
liac disease(36) and is the most frequent extra-intestinal symp-
tom related to the condition(37). However, evidence for
diagnosis of CD can be found in cases without anaemia, but
with an unexplained abnormality on a full blood count, such as
erythrocyte macrocytosis(38,39). Our results show that although
there were no signiﬁcant differences between the Hb levels in
the two groups, subjects with self-deﬁned sensitivity to gluten
had signiﬁcantly higher MCV and MCH when compared with
the control group (Table 4). MCV (erythrocyte size) together
with erythrocyte distribution width (variability in size of the
erythrocytes) were used by Bessman et al.(40) to construct an
improved classiﬁcation of anaemias.
Systemic inﬂammation is found to be behind the micronutrient
deﬁciencies in patients with CD even in absence of macroscopic
damage to the proximal small bowel(41). Our study also demon-
strates higher values for MPV and platelet distribution (or size
deviation) width (PDW) in GS subjects compared with healthy
controls. This might be indicative of platelet destruction, leading
to more freshly formed or younger platelets, which are larger in
size, circulating in the bloodstream. A possible association
between MPV and different inﬂammatory conditions has been
reported in the literature(42,43) and the results in the present study
may reﬂect an on-going intestinal inﬂammation.
Fatigue is a manifestation reported by subjects experiencing
gluten sensitivity(4,27). Information on the impact of fatigue on
quality of life and mental status (depression, anxiety and stress)
in the GS population is limited. In addition, to the best of our
knowledge, no comparisons have previously been made with
results obtained in a healthy control group. In our study, the
fatigue index for the GS group, although numerically higher,
was comparable with that of the control group, for example no
clinical implication was conﬁrmed. Moreover, comparisons
within the GS group did not reveal increased levels of tiredness
during the treatment periods when compared with the normal
habitual diet periods. These outcomes are not in line with the
results of the study conducted by Biesiekierski et al.(4) which
reported prominent effects on tiredness in this population,
whereas on a gluten-containing diet. Our study has the
advantage of determining the degree of the perception of
fatigue in healthy people as a physiological benchmark for
comparison and also taking into account other factors such
as physical activity.
Compared with the control group, the GS group scored higher
on the physical activity for leisure index. This suggests that the GS
group makes more health oriented choices for keeping active
during their leisure time and this may be partly the reason for the
lack of fatigue in the GS group, as it has been shown that physical
activity is one of the best ways to handle fatigue(44).
Previous studies have shown that short-term exposure to
gluten may have a negative effect on the mental state of people
who believe that they are sensitive to gluten(45,46). In this study,
both the control and the GS group were within the normal
range for all three subscales for depression, anxiety and stress
and no differences between the two groups were identiﬁed.
Our results conﬁrm the ﬁndings of Brottveit et al.(47) who report
no elevated scores for anxiety and depression.
The SF-36 survey is useful in the assessment of the quality of
life in relation to health. In this study comparison of the SF-36
scores did not reveal any differences between the control and
GS group with respect to any of the SF-36 subscales.
Our study has some important limitations. The small number
of participants did not allow us to perform GS subgroups ana-
lyses of discrete GI symptoms, extra-intestinal manifestations
and other related factors, which may play a role in the per-
ception of gluten sensitivity. Preferably a gluten-free control
would have been included, but this choice was not made
because of the inability to blind gluten-free bread against
wheat-based breads.
It is possible that other factors in bread such as FODMAP or
the nongluten ATI, which were not targeted by the enzyme, are
responsible for the observed effects. In support of FODMAP as
the causative agent, a recently published study investigating the
effects of gluten (without fructan) and fructan (without gluten)
on GI symptoms in individuals intolerant to wheat, rye or barley
reported that fructan caused an increase in GI symptoms
compared with the placebo control(48). It would have been
beneﬁcial to control for FODMAP intolerances. However,
because these resilient carbohydrates occur not just in wheat
but in all kind of foods, such interventions involve individual
consultation with a specialist dietitian, who advises on
4–8-week exclusion of foods high in FODMAP, followed by
graded reintroduction. Such an approach was beyond the scope
of this study and therefore a role for FODMAP in the bread
cannot be ruled out.
The lack of unambiguous biomarkers also makes it difﬁcult to
conﬁrm the true clinical status of the GS group with respect
to NCGS.
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In conclusion, the proline-speciﬁc ANPEP enzyme lowers the
immunogenic content of gluten by approximately 40% and can
be used in the production of wheat products comparable to
standard gluten content products in terms of taste, texture and
appearance. Only consumption of reference and biscuit ﬂour
bread increased GI symptoms in the GS subjects, compared
with their habitual diet. However, the 40% gluten reduction in
the ANPEP treated bread showed no treatment effect compared
with the other test breads. This may be due to levels of gluten in
ANPEP bread being insufﬁciently reduced to keep the GI
symptoms to pre-treatment levels.
Another explanation might be that gluten is not the main driver
of the symptoms in this population – a gluten-free or wheat-free
diet will not solve the GI symptoms if FODMAP, ATI or other
(presently unknown) factors are the main causes of symptoms.
This will clearly need to be considered in future studies.
The increase in GI symptoms after consumption of the test
breads may also be a consequence of a nocebo effect in the GS
population. Self-deﬁned sensitive to gluten individuals who
experience mild discomfort when consuming gluten, adopt a
low-gluten lifestyle as opposed to following a strict GFD. This
approach helps to reduce the GI symptoms severity to tolerable
levels. Consumption of wheat bread increases symptoms in the
GS subjects in comparison with their habitual diet. In compar-
ison with healthy controls, the GS subjects have a favourable
CVD lipid proﬁle and modiﬁed haematological proﬁle. Finally,
a low-gluten lifestyle was shown to have no effect on the
quality of life, fatigue or mental state of the GS population.
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